GREGORY FOX: Open Payments
NPI 1427230713 · GAUTIER, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,762 in 169 payments from 14 companies in 2025. Trend: 2023 $2,900 · 2024 $3,117 · 2025 $2,762
Food & beverage: $2,583Education: $179
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $513 |
| Teva Pharmaceuticals USA, Inc. | 23 | $445 |
| ABBVIE INC. | 40 | $382 |
| Lundbeck LLC | 19 | $325 |
| Supernus Pharmaceuticals, Inc. | 17 | $271 |
| Axsome Therapeutics, Inc. | 17 | $222 |
| Janssen Pharmaceuticals, Inc | 6 | $111 |
| Neurocrine BioSciences, Inc. | 4 | $104 |
| Otsuka America Pharmaceutical, Inc. | 4 | $89 |
| E.R. Squibb & Sons, L.L.C. | 3 | $89 |
Products named: CAPLYTA, VRAYLAR, Qelbree, REXULTI, Auvelity, UZEDY, ABILIFY ASIMTUFII, AUSTEDO XR.
Industry payments across MS — which companies pay providers there.
